← Back to Search

Diagnostic Test

Lung Ultrasound for Lung Transplant

N/A
Recruiting
Led By Tathagat Narula, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 0 to month 12
Awards & highlights
No Placebo-Only Group

Summary

This trial is looking for a safer and cheaper way to check for lung problems in lung transplant patients without using risky procedures.

Who is the study for?
This trial is for adults over 18 who have had a lung or heart-lung transplant. They must be symptom-free, with clear chest X-rays and normal breathing test results (FEV1) that haven't dropped more than 10% from their usual. People can't join if they can't consent or have conditions like subcutaneous emphysema that make it hard to get good ultrasound images.
What is being tested?
The study is testing the use of lung ultrasounds as a non-invasive method to detect lung rejection and infection in patients who've received lung transplants. It aims to find safer ways to diagnose these serious complications without invasive procedures.
What are the potential side effects?
Since the intervention involves only lung ultrasound, which is non-invasive, there are typically no side effects associated with this procedure.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 0 to month 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and month 0 to month 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Establish predictive value of lung ultrasound

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Receiving UltrasoundExperimental Treatment1 Intervention
Every patient will receive a lung ultrasound prior to each scheduled bronchoscopy until the study stops.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lung ultrasound
2021
N/A
~2160

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Bronchiectasis include antibiotics, mucoactive agents, and airway clearance techniques. Antibiotics target bacterial infections that exacerbate symptoms, reducing inflammation and preventing further lung damage. Mucoactive agents, such as hypertonic saline, help to thin and loosen mucus, making it easier to clear from the airways. Airway clearance techniques, including chest physiotherapy and exercise, facilitate the removal of mucus, improving lung function and reducing the risk of infections. These treatments are crucial for Bronchiectasis patients as they help manage symptoms, prevent exacerbations, and improve overall quality of life.
Self-management for bronchiectasis.Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial.

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,326 Previous Clinical Trials
3,059,404 Total Patients Enrolled
3 Trials studying Bronchiectasis
115 Patients Enrolled for Bronchiectasis
Tathagat Narula, MDPrincipal Investigator - Mayo Clinic
Mayo Clinic Hospital Jacksonville

Media Library

Lung ultrasound (Diagnostic Test) Clinical Trial Eligibility Overview. Trial Name: NCT04582279 — N/A
Bronchiectasis Research Study Groups: Receiving Ultrasound
Bronchiectasis Clinical Trial 2023: Lung ultrasound Highlights & Side Effects. Trial Name: NCT04582279 — N/A
Lung ultrasound (Diagnostic Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04582279 — N/A
~8 spots leftby Apr 2025